MetaCap

NextCure (NXTC) vs Rein Therapeutics (RNTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NextCure (NXTC) has outperformed Rein Therapeutics (RNTX) over the past year, losing 38.6% versus a loss of 77.2%. Over five years, NXTC leads with a -91.1% price change compared with -97.5% for RNTX. NextCure is the larger company by market cap ($29.5 million vs $29.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NXTC-38.63%RNTX-77.24%
+42%-25%-91%
Nov 21, 20251 yearNov 20, 2026
NXTC-90.73%RNTX-97.57%
+12%-46%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NXTC versus RNTX key metrics
MetricNXTCRNTX
Share price$6.45$0.3369
Market cap$29.53M$29.06M
1-day change-4.87%-8.38%
YTD return-54.55%-70.96%
1-year return-38.63%-77.24%
5-year return-91.07%-97.47%
EPS (TTM)$-6.78$-1.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-55.84M$-49.87M
52-week high$15.74$2.10
52-week low$1.55$0.284
Distance from 52-week high-59.02%-83.96%
Analyst consensusnonenone
Avg. price target upside+210.08%+1680.94%
Average volume79.46K586.68K
Shares outstanding4.58M86.27M
Employees4010
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NXTC has outperformed RNTX by 38.6 percentage points over the past year.

About NextCure

NXTC stock →

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

About Rein Therapeutics

RNTX stock →

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

NXTC vs RNTX FAQ

Which is bigger, NextCure or Rein Therapeutics?

NextCure (NXTC) is larger, with a market capitalization of $29.53M compared with $29.06M for Rein Therapeutics (RNTX).

Which stock has performed better over the past year, NXTC or RNTX?

NXTC returned -38.63% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.

Are NextCure and Rein Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons